Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by an overexpression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized monoclonal antibody against human EGFR. The aim of this study was to develop a population pharmacokinetic mo...

Descripción completa

Detalles Bibliográficos
Autores principales: de Castro-Suárez, Niurys, Trame, Mirjam N., Ramos-Suzarte, Mayra, Dávalos, José M., Bacallao-Mendez, Raymed A., Maceo-Sinabele, Anaelys R., Mangas-Sanjuán, Víctor, Reynaldo-Fernández, Gledys, Rodríguez-Vera, Leyanis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760646/
https://www.ncbi.nlm.nih.gov/pubmed/33256255
http://dx.doi.org/10.3390/pharmaceutics12121147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760646/
https://www.ncbi.nlm.nih.gov/pubmed/33256255
http://dx.doi.org/10.3390/pharmaceutics12121147

Ejemplares similares